Tirzepatide represents a groundbreaking treatment agent for individuals battling type 2 diabetes. As a dual stimulator, it targets both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic https://lulufqus553335.qowap.com/99591991/tirzepatide-a-novel-glp-1-and-gip-receptor-agonist